Metoprololo Eg (Metoprolol Tartrate)

Metoprolol selectively blocks β1‑adrenergic receptors in the heart, which reduces heart rate, myocardial contractility, and cardiac output. This leads to lower oxygen demand by the heart muscle and a reduction in systemic blood pressure, providing therapeutic benefit in cardiovascular diseases.

The appropriate dose of Metoprololo Eg is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any co‑existing health issues. Dosage may be adjusted over time to achieve optimal blood‑pressure control or symptom relief.

Safety data for metoprolol in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually and discuss alternatives when appropriate.

To request Metoprololo Eg, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol is a cardio‑selective (β1‑selective) beta‑blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. Its pharmacokinetic profile provides once‑ or twice‑daily dosing, which can improve adherence. Choice of beta‑blocker depends on the patient’s comorbidities, tolerance and clinical goals.

Metoprololo Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Metoprololo Eg is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events may include severe bradycardia, heart block, marked hypotension, worsening heart failure, bronchospasm in susceptible individuals, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, difficulty breathing, or signs of an allergic response.

Metoprololo Eg is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or overt decompensated heart failure. Caution is also advised for individuals with severe asthma or chronic obstructive pulmonary disease.